Study Finds MRI Contrast Agents Can Form Harmful Metal Nanoparticles in Some Patients
By
nikolay
A second-rack bagel that's nearly first-rack. Tasty stuff.
Summary
A new study published in Magnetic Resonance Imaging reveals that gadolinium-based contrast agents used in MRI scans may react with dietary compounds to form harmful metal nanoparticles that accumulate in the body. While these agents are typically excreted without issue, some patients retain toxic metals long after their MRI procedures, potentially explaining why certain individuals experience adverse effects from gadolinium retention.
Key quotes
· 4 pulledgadolinium contrast agents used in MRI scans may react with common dietary compounds to form harmful metal nanoparticles in the body
gadolinium-based contrast agents are injected to sharpen MRI images and are typically excreted without causing harm
New research offers a potential explanation for why some patients retain toxic metals long after undergoing an MRI
Published in the journal Magnetic Resonance Imaging, the findings show that gadolinium contrast agents used in MRI scans may react with common dietary compounds
You might also wanna read
Experimental pill daraxonrasib extends survival in advanced pancreatic cancer patients, study finds
Researchers reported that daraxonrasib, a novel experimental pill, helped patients with advanced pancreatic cancer live longer by blocking a
npr.org·2h ago
Spinach-derived photosynthetic treatment shows promise for dry eye disease
Scientists at the National University of Singapore have developed an experimental treatment for dry eye disease that uses photosynthetic mac
biotechniques.com·3h ago
Researchers develop phage-based preventive treatment for newborn meningitis caused by E. coli K1
Researchers from the Biozentrum, University of Basel, and ETH Zurich have developed a novel preventive treatment for newborn meningitis caus
biozentrum.unibas.ch·5h ago
Exploring the science behind quantum effects in healthcare: separating research from pseudoscience
The article explores the intersection of quantum physics and healthcare, distinguishing between pseudoscientific "quantum therapies" and leg
newscientist.com·9h ago
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·10h agoExperimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·10h ago